OS Therapies Initiates Commercial-Ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Application (BLA) Filing OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company dedicated to advancing immunotherapies and targeted…
Galderma (SWX:GALD) has announced that the European Commission has granted approval for Nemluvio, a groundbreaking biologic therapy, for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis within the European…
GeneDx Introduces ultraRapid Whole Genome Sequencing for NICU and PICU Patients, Offering Actionable Results in Just 48 Hours GeneDx (Nasdaq: WGS), a leading provider of genomic insights to improve health…
Tempus Partners with IFLI to Advance Development of Targeted Therapies for Follicular Lymphoma Tempus AI, Inc. and the Institute for Follicular Lymphoma Innovation (IFLI) Join Forces to Accelerate Development of…
Junevity Secures $10M to Advance Cell Reset Therapies for Longevity Junevity Secures $10M in Seed Funding to Develop Cell Reset Therapies Targeting Age-Related Diseases Junevity, a forward-thinking biotechnology company focused…
Quantum-Si and Leading Researchers to Showcase Advances in Next-Generation Protein Sequencing™ at US HUPO 2025 Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI,” or “the Company”), renowned as The Protein Sequencing Company™,…
RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company focused on developing targeted oncology therapies and commercializing the FDA-cleared RenovoCath device, recently showcased its latest pre-clinical data…
Newleos Launches with $93.5M to Advance Neuropsychiatric Treatments Newleos Therapeutics, Inc., a clinical-stage neuroscience company co-founded by Longwood Fund and experienced leaders in CNS drug development, has announced the successful…
Ensoma Secures Rare Pediatric Disease & Orphan Drug Status for EN-374 in Chronic Granulomatous Disease Ensoma, a genomic medicines company pioneering in vivo therapies to engineer the hematopoietic system, has…
Latent Labs Secures $50 Million to Pioneer AI-Driven Programmable Biology Latent Labs, an emerging leader in AI-powered biological programming, has officially stepped out of stealth mode, announcing a significant $50…
Opna Bio Secures Orphan Drug Designation for OPN-6602 in Multiple Myeloma Opna Bio, a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative oncology therapeutics, has announced that…
AltPep Corporation Welcomes Dr. Alan Colowick to Board of Directors AltPep Corporation, a privately held biotechnology company dedicated to developing early disease-modifying treatments and detection tools for amyloid diseases, has…